Details

NameSymbolSector
BAFNA PHARMACEUTICALS LIMITEDBAFNAPHPharmaceuticals
Open
109.42
High
109.42
Low
104.1
Close
109.42
Volume
85733
Exchange
nse
Time
14/08

Outlook

Score:  

7.5

Rating:  

GOOD

Candlestick Pattern

Candle pattern of Bafna Pharmaceuticals is  
Doji
Estimated Stoploss of Bafna Pharmaceuticals is ₹  
109.42
Bafna Pharmaceuticals has a  
Bearishℹ
 pattern. 
Formation of  
Doji
 candle pattern indicates the trend direction of Bafna Pharmaceuticals is  
Unpredictableℹ
. 

Trend

Bafna Pharmaceuticals is in  
Strong Uptrendℹ
. 
Price of Bafna Pharmaceuticals is  
Upℹ
 by  

26.61

%. 
Target
Buy @ 

88.72

Sell @ 

109.42

Volume

The trades of Bafna Pharmaceuticals have been in  
Immenseℹ
 volume. 
The volume trades for Bafna Pharmaceuticals are  
Bullishℹ
 with  
Strong Buyersℹ
The trade volume of Bafna Pharmaceuticals is  

Up

 by  

972.07

% 

Valuation

The current market price of Bafna Pharmaceuticals is  
Undervaluedℹ

Financials

Balance
The balance sheet of Bafna Pharmaceuticals is:  

Balanced

Cashflow
Bafna Pharmaceuticals has  
Maintainedℹ
 cash flow because there is  

Surplus

 of  

₹ 2cr

. It is  
Upℹ
 by  

133.33

%. 

(*Mar 2025)

50% i.e. ₹ 22cr earned in operatingℹ
47.73% i.e. ₹ 21cr spent in investingℹ
2.27% i.e. ₹ 1cr earned in financingℹ
0% in otherℹ
Bafna Pharmaceuticals has  
Poorℹ
 cash flow because there is  

Shortage

 of  

₹ 6cr

. It is  
Downℹ
 by  

185.71

%. 

(*Mar 2024)

37.5% i.e. ₹ 9cr earned in operatingℹ
62.5% i.e. ₹ 15cr spent in investingℹ
0% in financingℹ
0% in otherℹ
Income
The income of Bafna Pharmaceuticals is  

₹ 35cr

 and  

Profit

 is :  

₹ 3cr

(*Jun 2025)

Bafna Pharmaceuticals Profit is up by:  

200

% and Income is Down by:  

12.5

% 

(*Jun 2025)

The income of Bafna Pharmaceuticals is  

₹ 40cr

 and  

Profit

 is :  

₹ 1cr

(*Mar 2025)

Bafna Pharmaceuticals Profit is up by:  

100

% and Income is Up by:  

21.21

% 

(*Mar 2025)

The income of Bafna Pharmaceuticals is  

₹ 33cr

 and  

Loss

 is :  

₹ 0cr

(*Dec 2024)

Bafna Pharmaceuticals Losses increased by:  

100

% and Income is Down by:  

19.51

% 

(*Dec 2024)

By using this site you agree to the use of cookies to deliver a better site experience.